Clot Formation and Clot Stability in Patients With Severe Haemophilia A
Information source: University of Aarhus
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hemophilia A
Intervention: ReFacto (Recombinant factor VIII) and Tranexamic acid (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Aarhus Official(s) and/or principal investigator(s): Anne-Mette Hvas, MD, Ph.D., Principal Investigator, Affiliation: Aarhus University Hospital
Summary
In the present study we are examining the clot formation and clot stability in patients with
severe haemophilia A after they receive recombinat factor VIII and after addition of
tranexamic acid. Our hypothesis is that addition of tranexamic increases the clot stability.
The perpective of the study is to document whether it is relevant to use traneksamic acid in
surgery in patients with severe haemophilia A.
Clinical Details
Official title: Clot Formation and Clot Stability in Patients With Severe Haemophilia A - Effect of Recombinant Factor VIII and Tranexamic Acid
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Clot stability
Secondary outcome: clot formation,thrombine generation
Detailed description:
In the present study we are examining the clot formation and clot stability in patients with
severe haemophilia A after they receive recombinat factor VIII and after addition of
tranexamic acid. Our hypothesis is that addition of tranexamic increases the clot stability.
The perpective of the study is to document whether it is relevant to use traneksamic acid in
surgery in patients with severe haemophilia A.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Severe haemophilia A
- Above 17 years old
- Thrombocyt count above 100 x 109/l within the past two years
Exclusion Criteria:
- Received recombinant factor VIII with in the past 3 days
- Inhibitor against recombinant factor VIII
- HIV-positive
- Ongoing treatment for hepatitis C
- Known kidney disease
- Allergy against Tranexamic acid
- Not able to give informed consent
Locations and Contacts
Department of Clinical Biochemistry, Center for Haemophilia and Thrombosis, Aarhus 8200, Denmark
Additional Information
Starting date: January 2006
Last updated: November 15, 2006
|